CapsoVision Faces Stiff Competition in Medical Device Market

Analysts see higher potential upside for CapsoVision's rivals despite its affordable valuation

Published on Feb. 23, 2026

Got story updates? Submit your updates here. ›

CapsoVision (NASDAQ:CV) is a public company in the 'Surgical, Medical, And Dental Instruments And Supplies' industry, but it faces tough competition from its peers. Analysts believe CapsoVision's competitors have more favorable growth aspects, despite CapsoVision trading at a lower price-to-earnings ratio. The company is developing new capsule endoscopy products, including ones with AI-assisted features, to expand beyond its small bowel offerings, but regulatory approval and commercialization timelines remain uncertain.

Why it matters

The medical device industry is highly competitive, and CapsoVision's ability to grow its business and capture market share will depend on how it stacks up against its rivals in terms of technology, pricing, and regulatory approvals. The company's long-term success hinges on successfully navigating this competitive landscape.

The details

CapsoVision develops advanced imaging and AI technologies for its capsule endoscopy solutions to identify gastrointestinal tract abnormalities. The company's CapsoCam Plus capsule and software allow healthcare providers to panoramically visualize the small bowel. CapsoVision is working to add AI-assisted reading technology to the CapsoCam Plus and develop a new colon capsule endoscope product. However, the company faces regulatory uncertainty, as its 510(k) submissions to the FDA may be delayed, and it may not receive clearances in a timely manner or at all. CapsoVision's revenues have grown in recent years, but it remains dependent on its small bowel product line, and its ability to expand into new GI indications is crucial for long-term success.

  • CapsoVision began sales of its small-bowel capsule system internationally in 2012 and in the U.S. in 2017.
  • CapsoVision is targeting FDA 510(k) and EU submissions for its updated CapsoCam Plus with AI-assisted reading technology in the second half of 2025, with clearance and commercialization expected by the end of 2025.
  • CapsoVision is targeting CapsoCam Colon revenues in the U.S. in the second half of 2026 after receiving FDA 510(k) clearance, and in the EU in early 2027 after receiving a CE Mark.
  • CapsoVision plans to commence feasibility studies of CapsoCam's accuracy in screening esophageal varices in the second half of 2025 and detecting abnormalities indicative of pancreatic cancer in the first half of 2026.

The players

CapsoVision

A commercial-stage medical technology company that develops advanced imaging and artificial intelligence technologies for capsule endoscopy solutions.

CapsoCam Plus

CapsoVision's single-use capsule endoscope system that panoramically visualizes the small-bowel mucosa to investigate abnormalities.

CapsoCam Colon

CapsoVision's next pipeline capsule endoscope product that leverages the CapsoCam Plus design and incorporates AI to detect polyps and a 3D sensor to measure polyp size.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.